MCID: OPD006
MIFTS: 48

Opioid Addiction

Categories: Neuronal diseases

Aliases & Classifications for Opioid Addiction

MalaCards integrated aliases for Opioid Addiction:

Name: Opioid Addiction 25
Opiate Addiction 25 71
Opiate Dependence 25
Opioid Dependence 25

Classifications:



External Ids:

UMLS 71 C0524662

Summaries for Opioid Addiction

Genetics Home Reference : 25 Opioid addiction is a long-lasting (chronic) disease that can cause major health, social, and economic problems. Opioids are a class of drugs that act in the nervous system to produce feelings of pleasure and pain relief. Some opioids are legally prescribed by healthcare providers to manage severe and chronic pain. Commonly prescribed opioids include oxycodone, fentanyl, buprenorphine, methadone, oxymorphone, hydrocodone, codeine, and morphine. Some other opioids, such as heroin, are illegal drugs of abuse. Opioid addiction is characterized by a powerful, compulsive urge to use opioid drugs, even when they are no longer required medically. Opioids have a high potential for causing addiction in some people, even when the medications are prescribed appropriately and taken as directed. Many prescription opioids are misused or diverted to others. Individuals who become addicted may prioritize getting and using these drugs over other activities in their lives, often negatively impacting their professional and personal relationships. It is unknown why some people are more likely to become addicted than others. Opioids change the chemistry of the brain and lead to drug tolerance, which means that over time the dose needs to be increased to achieve the same effect. Taking opioids over a long period of time produces dependence, such that when people stop taking the drug, they have physical and psychological symptoms of withdrawal (such as muscle cramping, diarrhea, and anxiety). Dependence is not the same thing as addiction; although everyone who takes opioids for an extended period will become dependent, only a small percentage also experience the compulsive, continuing need for the drug that characterizes addiction. Opioid addiction can cause life-threatening health problems, including the risk of overdose. Overdose occurs when high doses of opioids cause breathing to slow or stop, leading to unconsciousness and death if the overdose is not treated immediately. Both legal and illegal opioids carry a risk of overdose if a person takes too much of the drug, or if opioids are combined with other drugs (particularly tranquilizers called benzodiazepines).

MalaCards based summary : Opioid Addiction, also known as opiate addiction, is related to opiate dependence and chronic pain. An important gene associated with Opioid Addiction is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Valproic acid and Ribavirin have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Opioid Addiction

Diseases related to Opioid Addiction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 213)
# Related Disease Score Top Affiliating Genes
1 opiate dependence 31.2 OPRM1 OPRK1 OPRD1 DRD2
2 chronic pain 31.2 OPRM1 COMT
3 personality disorder 30.8 DRD2 COMT CCK
4 substance abuse 30.6 OPRM1 OPRK1 OPRD1 DRD2 COMT
5 alcohol use disorder 30.5 OPRM1 DRD2 COMT
6 polysubstance abuse 30.5 DRD2 COMT
7 heroin dependence 30.2 OPRM1 OPRD1 DRD2 COMT
8 social phobia 30.0 DRD2 COMT CCK
9 opioid abuse 30.0 PNOC OPRM1 OPRK1 OPRD1 DRD2 CCK
10 withdrawal disorder 30.0 PNOC OPRM1 OPRK1 OPRD1 DRD2
11 cocaine dependence 30.0 OPRM1 OPRK1 OPRD1 DRD2 COMT
12 drug dependence 30.0 PNOC OPRM1 OPRK1 OPRD1 DRD2
13 somatoform disorder 30.0 OPRM1 OPRD1 COMT
14 eating disorder 29.9 OPRM1 DRD2 COMT CCK
15 trigeminal neuralgia 29.9 OPRM1 OPRK1 OPRD1
16 amnestic disorder 29.9 OPRM1 OPRK1 OPRD1 DRD2
17 tobacco addiction 29.8 OPRM1 DRD2 CYP2B6 COMT
18 morphine dependence 29.8 OPRM1 OPRK1 OPRD1 CCK
19 substance dependence 29.8 OPRM1 OPRK1 OPRD1 DRD2 COMT
20 diarrhea 29.8 OPRM1 OPRK1 CCK ABCB1
21 pain agnosia 29.7 PNOC OPRM1 OPRK1 OPRD1 CCK
22 constipation 29.7 OPRM1 OPRK1 OPRD1 CCK
23 obsessive-compulsive disorder 29.5 GRIN2A DRD2 COMT CCK
24 panic disorder 29.5 DRD2 COMT CCKBR CCKAR CCK
25 attention deficit-hyperactivity disorder 29.3 OPRM1 GRIN2A DRD2 COMT ABCB1
26 psychotic disorder 29.3 OPRM1 GRIN2A DRD2 COMT CCK
27 neonatal abstinence syndrome 29.2 PNOC OPRM1 OPRK1 OPRD1 CYP2B6 COMT
28 major depressive disorder 29.0 OPRM1 GRIN2A DRD2 CYP2B6 COMT ABCB1
29 disease of mental health 28.9 OPRM1 OPRK1 OPRD1 GRIN2A DRD2 COMT
30 migraine with or without aura 1 28.8 PNOC OPRM1 OPRK1 OPRD1 DRD2 COMT
31 pertussis 28.8 OPRM1 MAPK3 MAPK1
32 fibromyalgia 28.5 PNOC OPRM1 OPRK1 OPRD1 GRIN2D DRD2
33 anxiety 28.3 PNOC OPRM1 OPRK1 OPRD1 GRIN2A DRD2
34 autism 28.3 OPRM1 MAPK3 GRIN2D GRIN2A DRD2 COMT
35 alcohol dependence 28.3 PNOC OPRM1 OPRK1 OPRD1 GRIN2A DRD2
36 schizophrenia 27.1 OPRM1 GRIN3B GRIN2D GRIN2A DRD2 COMT
37 opioid dependence 1 12.7
38 schizophrenia 5 10.4 DRD2 COMT
39 cocaine abuse 10.3
40 tardive dyskinesia 10.3 DRD2 COMT
41 hallucinogen dependence 10.3 OPRM1 DRD2 COMT
42 avoidant personality disorder 10.3
43 drug psychosis 10.2 DRD2 COMT
44 cannabis abuse 10.2 OPRM1 DRD2 COMT
45 drug-induced mental disorder 10.2 DRD2 COMT
46 trigeminal nerve disease 10.2 OPRM1 OPRK1 OPRD1
47 acalculous cholecystitis 10.2 CCKAR CCK
48 substance-induced psychosis 10.2 DRD2 COMT
49 pedophilia 10.2
50 gastroparesis 10.1 DRD2 CCK ABCB1

Comorbidity relations with Opioid Addiction via Phenotypic Disease Network (PDN):


Acute Cystitis Anxiety
Deficiency Anemia Dysthymic Disorder
Heart Disease Hypertension, Essential
Major Depressive Disorder Osteoporosis

Graphical network of the top 20 diseases related to Opioid Addiction:



Diseases related to Opioid Addiction

Symptoms & Phenotypes for Opioid Addiction

MGI Mouse Phenotypes related to Opioid Addiction:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.21 ABCB1 CCKAR CCKBR COMT DRD2 GRIN2A
2 homeostasis/metabolism MP:0005376 9.97 ABCB1 CCK CCKAR CCKBR COMT DRD2
3 endocrine/exocrine gland MP:0005379 9.96 ABCB1 CCK CCKAR CCKBR COMT DRD2
4 digestive/alimentary MP:0005381 9.92 ABCB1 CCKAR CCKBR DRD2 MAPK1 MAPK3
5 integument MP:0010771 9.65 CCKBR DRD2 GRIN2A GRIN2D MAPK1 MAPK3
6 nervous system MP:0003631 9.44 ABCB1 CCK CCKAR CCKBR COMT DRD2

Drugs & Therapeutics for Opioid Addiction

Drugs for Opioid Addiction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 281)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
2
Ribavirin Approved Phase 4 36791-04-5 37542
3
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
5
Rifampicin Approved Phase 4 13292-46-1 5458213 5381226
6
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
7
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 5095 497540
8
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
9
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
10
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
11
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
12
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
13
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
14
Rifapentine Approved, Investigational Phase 4 61379-65-5 6323497
15
Tapentadol Approved Phase 4 175591-23-8 9838022
16
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
17
Methadone Approved Phase 4 76-99-3 4095
18
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
19
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
20
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
21
Methadyl Acetate Experimental, Illicit Phase 4 509-74-0 10517
22 GABA Agents Phase 4
23 Cholinergic Agents Phase 4
24 Nicotinic Agonists Phase 4
25 Pharmaceutical Solutions Phase 4
26 Anesthetics, General Phase 4
27 Anesthetics, Intravenous Phase 4
28 interferons Phase 4
29 Interferon alpha-2 Phase 4
30 Interferon-alpha Phase 4
31 Immunologic Factors Phase 4
32 Adjuvants, Anesthesia Phase 4
33 Cytochrome P-450 CYP3A Inducers Phase 4
34 Dopamine agonists Phase 4
35 Ketorolac Tromethamine Phase 4
36 Neurotransmitter Agents Phase 4
37 Adrenergic Agents Phase 4
38 Anti-Infective Agents Phase 4
39 Anesthetics, Local Phase 4
40 Anesthetics Phase 4
41 Excitatory Amino Acid Antagonists Phase 4
42 Excitatory Amino Acids Phase 4
43 Hormones Phase 4
44 Anticonvulsants Phase 4
45 Antimanic Agents Phase 4
46 Anti-Anxiety Agents Phase 4
47 Antibiotics, Antitubercular Phase 4
48 Antitubercular Agents Phase 4
49 Anti-Bacterial Agents Phase 4
50 Antimetabolites Phase 4

Interventional clinical trials:

(show top 50) (show all 502)
# Name Status NCT ID Phase Drugs
1 An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Treatment in HIV Primary Care Settings Unknown status NCT00124358 Phase 4 Buprenorphine
2 SPNS Buprenorphine and Integrated HIV Care Evaluation and Support Center: Integration of Buprenorphine and HIV Treatment Using the OASIS Model Unknown status NCT00241930 Phase 4
3 Buprenorphine/Nx Treatment of Heroin Dependence-A Compassionate Use Study Completed NCT00015340 Phase 4 Buprenorphine/naloxone
4 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
5 A Randomized Controlled Trial Comparing Buprenorphine and Methadone for Treatment in Opioid Dependent Chronic Back Pain Patients Completed NCT01559454 Phase 4 Methadone;Buprenorphine/naloxone
6 Integrating Buprenorphine Into the SFGH AIDS Program (Patient Evaluation Study) Completed NCT00263458 Phase 4
7 Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence Completed NCT00555425 Phase 4
8 An Open Multi-center Trial of Suboxone® (Buprenorphine/Naloxone) Treatment Among Opiate-Dependent Subjects Completed NCT00901875 Phase 4 Buprenorphine + naloxone (Suboxone);Buprenorphine + naloxone (Suboxone)
9 On-Site Addiction Treatment With Buprenorphine in HIV Clinical Care Settings Completed NCT00317460 Phase 4
10 VIVITROL® (Naltrexone for Extended Release Injectable Suspension (XR-NTX)) for Opioid Dependent Inmates Released From Prison Completed NCT01563718 Phase 4 naltrexone for extended release injectable suspension
11 Effects of Ketamine On Precipitated Opioid Withdrawal Under General Anaesthesia Completed NCT00300794 Phase 4 Ketamine
12 A Randomized Controlled Trial Comparing Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed NCT00879996 Phase 4 Methadone;Buprenorphine/naloxone
13 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects Completed NCT00605033 Phase 4 Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484;Subutex, Buprenorphine Hydrochloride, SCH 28444
14 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4 Buprenorphine;Valproate
15 A Phase 4, Pilot, Open-label Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration Completed NCT01453374 Phase 4 VIVITROL 380mg
16 A Multi-center, Open-Label, 24-Week, Follow-Up Study to Assess Safety, Efficacy, and Treatment Adherence For Maintenance Treatment of Opioid Dependence With OX219 Completed NCT01903005 Phase 4 Higher bioavailability BNX sublingual tablets
17 Feasibility Study of Take-Home LAAM Medication Completed NCT00000300 Phase 4 LAAM
18 Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy Completed NCT01045278 Phase 4 Pegylated interferon-alfa-2b and ribavirin
19 A Multicenter Safety Trial of Buprenorphine/Naloxone for the Treatment of Opiate Dependence Completed NCT00007527 Phase 4 naloxone;buprenorphine
20 Project STRIDE2 - Seek/Test/Retain: PLWHA and Opioid Users in Washington, DC Completed NCT03583138 Phase 4 buprenorphine
21 A Single Center, Randomized, 2 Way Cross-Over, Phase 4 Study Comparing Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 Including Ease of Use, Taste Preference, Dissolution Time, Desire to Abuse, and Overall Acceptance In Buprenorphine/Naloxone Treated Opioid Dependent Population Completed NCT02038790 Phase 4 Suboxone Sublingual Film;Zubsolv sublingual tablets
22 Intensive Outpatient v. Outpatient Treatment With Buprenorphine Among African Americans Completed NCT01096550 Phase 4
23 Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment Completed NCT00844272 Phase 4
24 Neurocognitive Effects of Opiate Agonist Treatment Completed NCT01733693 Phase 4 Buprenorphine;Methadone
25 Counseling for Primary Care Office-based Buprenorphine Completed NCT00595764 Phase 4
26 Buprenorphine to Improve HIV Care Engagement and Outcomes: A Randomized Trial (BRAVO) Completed NCT01936857 Phase 4 Buprenorphine/naloxone;Methadone Maintenance Therapy
27 CTN-0051: Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment Completed NCT02032433 Phase 4 Extended-Release Naltrexone;Buprenorphine-Naloxone
28 Feasibility, Mechanism of Action and Potential Side Effects of Extended Release Depot Naltrexone in Opioid Dependent Patients Completed NCT01471145 Phase 4 Naltrexone
29 Relapse Prevention to Reduce HIV Among Women Prisoners Completed NCT00763958 Phase 4 Placebo;Buprenorphine
30 Naltrexone: Consummatory Behaviors in Alcoholic Women Completed NCT00000448 Phase 4 naltrexone;Placebo
31 Health Services Research: Extended Release Naltrexone for Opioid-Dependent Youth Completed NCT01843023 Phase 4 Extended Release Naltrexone;Buprenorphine
32 An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence Completed NCT01047527 Phase 4 Transdermal nicotine patch
33 Effects of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sublingual and Intravenous Buprenorphine: A Four-phase Cross-over Study in Healthy Subjects. Completed NCT01854489 Phase 4 Placebo;Rifampicin;Buprenorphine
34 Randomized, Double-blind, Placebo-controlled Study of Naltrexone for Impulse Control Disorders in Parkinson's Disease Completed NCT01052831 Phase 4 Naltrexone;Placebo
35 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users Completed NCT00604188 Phase 4 Suboxone (SCH 000484);Subutex (SCH 028444)
36 Pain Control in the Nuss Procedure: A Prospective, Randomized Trial of Cryoanalgesia vs. Thoracic Epidural Completed NCT02721017 Phase 4 Thoracic epidural (ropivicaine, fentanyl)
37 Use of Liposomal Bupivacaine for Postoperative Pain Management After Arthroscopic Rotator Cuff Repair Completed NCT03149887 Phase 4 Liposomal bupivacaine;Placebo
38 Multimodal Pain Management for Cesarean Delivery: A Randomized Control Trial Completed NCT02922985 Phase 4 Intravenous acetominophen;Ketorolac, intramuscular;Bupivacaine, subcutaneous;Normal saline
39 A Feasibility Study for Testing the Effects of Extended-release Naltrexone (Vivitrol) on Recidivism and Other Participant Outcomes in Drug Court Settings Completed NCT02978417 Phase 4 Naltrexone for extended-release injectable suspension;Oral naltrexone
40 Long Acting Naltrexone for Opioid Addiction: the Importance of Mental, Physical and Societal Factors for Sustained Abstinence and Recovery Recruiting NCT03647774 Phase 4 Extended release naltrexone
41 Minimizing Narcotic Analgesics After Thyroid or Parathyroid Surgery Recruiting NCT03469310 Phase 4 Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
42 Optimizing Patient Centered-Care: A Pragmatic Randomized Control Trial Comparing Models of Care in the Management of Prescription Opioid Misuse (OPTIMA Trial) Recruiting NCT03033732 Phase 4 Methadone;Buprenorphine-Naloxone
43 Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings Recruiting NCT03089983 Phase 4 Naltrexone;Methadone;Isoniazid;Rifapentine
44 Houston Emergency Opioid Engagement System (HEROES) Recruiting NCT03396276 Phase 4 Suboxone
45 A Randomized Clinical Trial of Single Dose Liposomal Bupivacaine Delivered Via VATS Intercostal Nerve Block vs. Continuous Bupivacaine Infusion Delivered Via Indwelling Subscapular Catheter After Surgical Stabilization of Rib Fractures Recruiting NCT03305666 Phase 4 Liposomal bupivacaine injection;Bupivacaine indwelling catheter
46 RCT of Gabapentin Versus Placebo for Postoperative Pain After Sacrospinous Ligament Fixation for Pelvic Organ Prolapse Recruiting NCT03123861 Phase 4 Gabapentin;Placebo oral capsule
47 Safety and Efficacy of Pre-emptive Tapentadol vs Pregabalin in Post Operative Pain Following Unilateral Total Knee Arthroplasty- A Randomised, Double Blind, Active Control, Clinical Trial Recruiting NCT03604354 Phase 4 Tapentadol 100 MG Oral Tablet;Pregabalin 150mg
48 Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery Recruiting NCT03893734 Phase 4 methadone;Hydromorphone
49 Bridging Care to HCV Treatment Among Opiate Dependent Patients on Buprenorphine/Naloxone Maintenance Therapy: A Pilot Study of Treating HCV With Epclusa at a Psychiatrist-staffed Outpatient Addiction Clinic Active, not recruiting NCT03235154 Phase 4 sofosbuvir/velpatasvir
50 Biomarkers of Disease and Response to Treatment in Opioid Addiction Active, not recruiting NCT02324725 Phase 4 Naltrexone

Search NIH Clinical Center for Opioid Addiction

Genetic Tests for Opioid Addiction

Anatomical Context for Opioid Addiction

MalaCards organs/tissues related to Opioid Addiction:

40
Brain, Testes, Cortex, Liver, Heart, Prefrontal Cortex, Amygdala

Publications for Opioid Addiction

Articles related to Opioid Addiction:

(show top 50) (show all 1903)
# Title Authors PMID Year
1
Enhanced Recovery After Surgery (ERAS): A Perspective Review of Postoperative Pain Management Under ERAS Pathways and Its Role on Opioid Crisis in the United States. 61
31868759 2020
2
Kidney stones and the opioid epidemic: recent developments and review of the literature. 61
31834080 2020
3
Hispanics, Addictions, and the Opioid Epidemic: Brief Report. 61
31747797 2020
4
Nursing Education in the Midst of the Opioid Crisis. 61
31358464 2020
5
Double dissociation of inhibitory effects between the hippocampal TET1 and TET3 in the acquisition of morphine self-administration in rats. 61
32031744 2020
6
Cannabis Use Motivations among Adults Prescribed Opioids for Pain versus Opioid Addiction. 61
31375419 2020
7
Opioid versus opioid-free analgesia after surgical discharge: protocol for a systematic review and meta-analysis. 61
32014880 2020
8
Glial neuroimmune signaling in opioid reward. 61
31790721 2020
9
The effect of Clinical Practice Guidelines on prescribing practice in mental health: A systematic review. 61
31732189 2020
10
Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine. 61
31810594 2020
11
D1- but not D2-like dopamine receptor antagonist in the CA1 region of the hippocampus reduced stress-induced reinstatement in extinguished morphine-conditioning place preference in the food-deprived rats. 61
32040018 2020
12
Trends in Mental Well-Being of Non-Hispanic White Children of Midlife Parents With Low Education. 61
31976358 2020
13
The Benefits of Opioid Free Anesthesia and the Precautions Necessary When Employing It. 61
31712783 2020
14
A call for consensus in defining efficacy in clinical trials for opioid addiction: combined results from a systematic review and qualitative study in patients receiving pharmacological assisted therapy for opioid use disorder. 61
31907000 2020
15
An Ultra-Brief Mindfulness-Based Intervention for Patients in Treatment for Opioid Addiction with Buprenorphine: A Primary Care Feasibility Pilot Study. 61
31825240 2020
16
Epigenetic Mechanisms of Opioid Addiction. 61
31477236 2020
17
Neurobiology of Opioid Addiction: Opponent Process, Hyperkatifeia, and Negative Reinforcement. 61
31400808 2020
18
Preventing Morphine Seeking Behavior through the Re-engineering of Vincamine's Biological Activity. 61
31913038 2020
19
Opioid crisis: Placing blame or fixing the problem. 61
31913211 2020
20
Pain management strategies in penile implantation. 61
31464206 2020
21
Effects of oxycodone on sensitivity to reinforcement magnitude: implications for effects of opioids on impulsive and risky choice. 61
31922965 2020
22
Non-medical use of loperamide in the UK and the USA. 61
31424512 2020
23
Implications of Drug Use Disorders on Spine Surgery. 61
31926361 2020
24
Views of Rural US Adults About Health and Economic Concerns. 61
31913496 2020
25
Prefrontal GABA and glutamate levels correlate with impulsivity and cognitive function of prescription opioid addicts: A 1 H-magnetic resonance spectroscopy study. 61
31599080 2020
26
Understanding Opioid Use Disorder (OUD) using tree-based classifiers. 61
31962227 2020
27
Effects of social exclusion and physical pain in chronic opioid maintenance treatment: fMRI correlates. 61
30497842 2019
28
Barriers and Facilitators to Intraoperative Alternatives to Opioids: Examining CRNA Perspectives and Practices. 61
31920199 2019
29
Ethics of Opioid Prescriber Regulations: Physicians, Patients, and Pain. 61
31800432 2019
30
Variation on the CRH Gene Determines the Different Performance of Opioid Addicts and Healthy Controls in the IOWA Gambling Task. 61
31805553 2019
31
Inhibition of naltrexone on relapse in methamphetamine self-administration and conditioned place preference in rats. 61
31542477 2019
32
Adopting Graduate Competencies in Opioid Prescribing for Massachusetts Physician Assistant Programs: A Statewide Public Health Response. 61
31664008 2019
33
Provider perceptions of system-level opioid prescribing and addiction treatment policies. 61
30856591 2019
34
Computational framework for predictive PBPK-PD-Tox simulations of opioids and antidotes. 61
31396799 2019
35
A patient-centered approach to tapering opioids. 61
31860698 2019
36
Too few doctors prepared to provide opioid addiction treatment in the north. 61
31844028 2019
37
Physical exercise modifies behavioral and molecular parameters related to opioid addiction regardless of training time. 61
31899030 2019
38
Opioid Addiction Stigma: The Intersection of Race, Social Class, and Gender. 61
31868067 2019
39
Poor Access to Opioid Addiction Care for Total Joint Arthroplasty Patients. 61
31785137 2019
40
Vortioxetine use may cause false positive immunoassay results for urine methadone. 61
31469980 2019
41
The role of the gut microbiome in opioid use. 61
31895059 2019
42
Opioid addiction and the cerebellum. 61
31526817 2019
43
On the early life origins of vulnerability to opioid addiction. 61
31822817 2019
44
Adjunctive memantine for opioid use disorder treatment: A systematic review. 61
31757263 2019
45
Parental morphine exposure affects repetitive grooming actions and marble burying behavior in the offspring: Potential relevance for obsessive-compulsive like behavior. 61
31693870 2019
46
Computational Markers of Risky Decision-making for Identification of Temporal Windows of Vulnerability to Opioid Use in a Real-world Clinical Setting. 61
31812982 2019
47
Orexin-1 Receptor Signaling in Ventral Pallidum Regulates Motivation for the Opioid Remifentanil. 61
31641055 2019
48
Pharmacological characterization of 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(3'-fluoro-4'-pyridyl)acetamido]morphinan (NFP) as a dual selective MOR/KOR ligand with potential applications in treating opioid use disorder. 61
31743739 2019
49
Heroin Cue-Evoked Astrocytic Structural Plasticity at Nucleus Accumbens Synapses Inhibits Heroin Seeking. 61
31495448 2019
50
Machine learning: assessing neurovascular signals in the prefrontal cortex with non-invasive bimodal electro-optical neuroimaging in opiate addiction. 61
31797878 2019

Variations for Opioid Addiction

Expression for Opioid Addiction

Search GEO for disease gene expression data for Opioid Addiction.

Pathways for Opioid Addiction

Pathways related to Opioid Addiction according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.93 PNOC OPRM1 OPRK1 OPRD1 MAPK3 MAPK1
2
Show member pathways
12.65 PNOC OPRM1 OPRK1 OPRD1 GRIN3B GRIN2D
3
Show member pathways
12.37 MAPK3 MAPK1 GRIN3B GRIN2D GRIN2A DRD2
4
Show member pathways
12.24 MAPK3 MAPK1 CCKBR CCK
5 12.17 GRIN3B GRIN2D GRIN2A DRD2
6
Show member pathways
12.07 GRIN2D GRIN2A CCKBR CCKAR
7
Show member pathways
11.87 MAPK3 MAPK1 GRIN2D GRIN2A DRD2
8 11.86 OPRD1 MAPK3 MAPK1
9
Show member pathways
11.82 GRIN3B GRIN2D GRIN2A
10 11.77 MAPK3 MAPK1 GRIN3B GRIN2D GRIN2A DRD2
11
Show member pathways
11.76 CYP2B6 COMT ABCB1
12
Show member pathways
11.74 GRIN3B GRIN2D GRIN2A DRD2
13 11.64 MAPK3 MAPK1 DRD2
14 11.49 MAPK3 MAPK1 GRIN2D GRIN2A
15
Show member pathways
11.48 CYP2B6 COMT ABCB1
16 11.21 GRIN3B GRIN2D GRIN2A
17 11.16 MAPK3 MAPK1 ABCB1
18 10.91 MAPK3 MAPK1
19 10.91 MAPK3 MAPK1
20 10.88 MAPK3 MAPK1
21 10.87 MAPK3 MAPK1
22 10.87 MAPK3 MAPK1
23 10.83 MAPK3 MAPK1
24 10.76 MAPK3 MAPK1
25 10.67 CCKBR CCK
26 10.66 MAPK3 MAPK1
27 10.62 MAPK3 MAPK1

GO Terms for Opioid Addiction

Cellular components related to Opioid Addiction according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.3 OPRM1 OPRK1 OPRD1 MAPK3 MAPK1 GRIN3B
2 integral component of plasma membrane GO:0005887 10.05 OPRM1 OPRK1 OPRD1 GRIN2D GRIN2A DRD2
3 cell GO:0005623 10.01 MAPK3 MAPK1 GRIN2D GRIN2A DRD2 CCKBR
4 dendrite GO:0030425 9.89 PNOC OPRM1 DRD2 COMT CCK
5 axon GO:0030424 9.8 OPRM1 MAPK1 DRD2 COMT CCK
6 integral component of presynaptic membrane GO:0099056 9.65 OPRM1 OPRD1 DRD2
7 perikaryon GO:0043204 9.62 OPRM1 MAPK1 DRD2 CCK
8 axon terminus GO:0043679 9.61 PNOC OPRD1 DRD2
9 postsynaptic membrane GO:0045211 9.55 OPRD1 GRIN3B GRIN2D GRIN2A COMT
10 pseudopodium GO:0031143 9.52 MAPK3 MAPK1
11 plasma membrane GO:0005886 9.47 PNOC OPRM1 OPRK1 OPRD1 MAPK3 MAPK1
12 postsynaptic density membrane GO:0098839 9.43 GRIN3B GRIN2D GRIN2A
13 spine apparatus GO:0097444 9.37 OPRM1 OPRD1
14 NMDA selective glutamate receptor complex GO:0017146 9.13 GRIN3B GRIN2D GRIN2A

Biological processes related to Opioid Addiction according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.21 PNOC OPRM1 OPRK1 OPRD1 MAPK1 DRD2
2 G protein-coupled receptor signaling pathway GO:0007186 10.06 PNOC OPRM1 OPRK1 OPRD1 DRD2 CCKBR
3 response to drug GO:0042493 9.98 GRIN2A DRD2 COMT ABCB1
4 chemical synaptic transmission GO:0007268 9.96 PNOC OPRK1 MAPK1 GRIN2A
5 response to lipopolysaccharide GO:0032496 9.9 OPRM1 MAPK3 MAPK1 COMT
6 response to ethanol GO:0045471 9.86 OPRM1 GRIN2A DRD2
7 response to toxic substance GO:0009636 9.85 MAPK3 MAPK1 DRD2
8 axonogenesis GO:0007409 9.85 DRD2 CCKAR CCK
9 locomotory behavior GO:0007626 9.84 OPRM1 OPRK1 DRD2
10 neuropeptide signaling pathway GO:0007218 9.83 PNOC OPRM1 OPRK1 OPRD1
11 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.8 OPRM1 OPRK1 OPRD1
12 visual learning GO:0008542 9.79 GRIN2A DRD2 CCK
13 long-term synaptic potentiation GO:0060291 9.78 MAPK1 GRIN2D GRIN2A
14 modulation of chemical synaptic transmission GO:0050804 9.78 GRIN3B GRIN2D GRIN2A DRD2
15 synaptic transmission, glutamatergic GO:0035249 9.75 GRIN3B GRIN2D GRIN2A
16 face development GO:0060324 9.69 MAPK3 MAPK1
17 positive regulation of telomere capping GO:1904355 9.69 MAPK3 MAPK1
18 eating behavior GO:0042755 9.69 OPRM1 OPRD1 CCK
19 cellular response to dopamine GO:1903351 9.68 MAPK3 MAPK1
20 behavioral response to ethanol GO:0048149 9.68 OPRM1 DRD2
21 regulation of ossification GO:0030278 9.67 MAPK3 MAPK1
22 ionotropic glutamate receptor signaling pathway GO:0035235 9.67 GRIN3B GRIN2D GRIN2A
23 excitatory postsynaptic potential GO:0060079 9.67 OPRM1 GRIN2D GRIN2A DRD2
24 regulation of stress-activated MAPK cascade GO:0032872 9.66 MAPK3 MAPK1
25 outer ear morphogenesis GO:0042473 9.65 MAPK3 MAPK1
26 regulation of early endosome to late endosome transport GO:2000641 9.65 MAPK3 MAPK1
27 excitatory chemical synaptic transmission GO:0098976 9.65 GRIN2D GRIN2A
28 Bergmann glial cell differentiation GO:0060020 9.64 MAPK3 MAPK1
29 calcium ion transmembrane import into cytosol GO:0097553 9.64 GRIN2D GRIN2A
30 trachea formation GO:0060440 9.63 MAPK3 MAPK1
31 regulation of cellular pH GO:0030641 9.63 MAPK3 MAPK1
32 caveolin-mediated endocytosis GO:0072584 9.62 MAPK3 MAPK1
33 startle response GO:0001964 9.61 GRIN2D GRIN2A DRD2
34 regulation of Golgi inheritance GO:0090170 9.59 MAPK3 MAPK1
35 response to epidermal growth factor GO:0070849 9.58 MAPK3 MAPK1
36 dopamine metabolic process GO:0042417 9.58 GRIN2A DRD2 COMT
37 cardiac neural crest cell development involved in heart development GO:0061308 9.57 MAPK3 MAPK1
38 cholecystokinin signaling pathway GO:0038188 9.55 CCKBR CCKAR
39 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.55 OPRM1 OPRK1 OPRD1 CCKBR CCKAR
40 adenylate cyclase-inhibiting opioid receptor signaling pathway GO:0031635 9.54 OPRM1 OPRK1
41 opioid receptor signaling pathway GO:0038003 9.5 OPRM1 OPRK1 OPRD1
42 sensory perception GO:0007600 9.43 PNOC OPRM1 OPRK1
43 sensory perception of pain GO:0019233 9.35 OPRM1 OPRK1 MAPK3 MAPK1 GRIN2A
44 regulation of sensory perception of pain GO:0051930 9.02 OPRM1 OPRD1 GRIN2D COMT CCK

Molecular functions related to Opioid Addiction according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.93 OPRM1 OPRK1 OPRD1 DRD2 CCKBR CCKAR
2 peptide binding GO:0042277 9.65 OPRM1 OPRK1 OPRD1
3 transmitter-gated ion channel activity involved in regulation of postsynaptic membrane potential GO:1904315 9.58 GRIN3B GRIN2D GRIN2A
4 ligand-gated ion channel activity GO:0015276 9.54 GRIN3B GRIN2D GRIN2A
5 MAP kinase kinase activity GO:0004708 9.52 MAPK3 MAPK1
6 MAP kinase activity GO:0004707 9.51 MAPK3 MAPK1
7 NMDA glutamate receptor activity GO:0004972 9.49 GRIN2D GRIN2A
8 glutamate-gated calcium ion channel activity GO:0022849 9.43 GRIN2D GRIN2A
9 glutamate receptor activity GO:0008066 9.43 GRIN3B GRIN2D GRIN2A
10 neuropeptide binding GO:0042923 9.33 OPRM1 OPRK1 OPRD1
11 cholecystokinin receptor activity GO:0004951 9.32 CCKBR CCKAR
12 ionotropic glutamate receptor activity GO:0004970 9.13 GRIN3B GRIN2D GRIN2A
13 opioid receptor activity GO:0004985 8.8 OPRM1 OPRK1 OPRD1

Sources for Opioid Addiction

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....